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Abstract: Although glycemic control is an important and effective way to prevent and minimize 
the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which 
often proves difficult to manage. Most affected patients will eventually require therapy with 
multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 
(DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 
diabetes, which has become widely incorporated into clinical practice. This review summarizes 
the available data on the efficacy, safety, and tolerability of these medications.
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Introduction
Although glycemic control is an important and effective way to prevent and minimize 
the worsening of diabetes-related complications, type 2 diabetes is a progressive dis-
ease which often proves difficult to manage.1–3 Most affected patients will eventually 
require therapy with multiple medications in order to reach appropriate glycemic 
targets.4 The number of new glucose-lowering therapies has increased dramatically 
over the past decade, and prospective agents continue to be developed as new physi-
ologic targets are identified. There are a number of important considerations when 
choosing antihyperglycemic therapies for treatment of patients with type 2 diabetes. 
These include the glucose-lowering potency of the medication; the presence of co-
morbid conditions in the patient being treated; possible adverse side effects of the 
drugs being used; the risk of hypoglycemia with given classes or combinations of 
agents; and the potential for weight gain associated with various drug classes. Addi-
tional considerations include the impact of therapy on cardiovascular health and 
potential for beta cell preservation, as well as concern for carcinogenic or mitogenic 
properties of existing therapies.
The dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs represents one of the 
newest groups available for diabetes treatment. Two DPP-4 inhibitors are currently 
available in the United States: sitagliptin and saxagliptin. Vildagliptin is a third DPP-4 
inhibitor available in Europe and many other countries, although approval in the US 
is still pending. Alogliptin and linagliptin are among the DPP-4 inhibitors still under 
development. These agents have an attractive mechanism of action, described in detail 
in the following sections, which complements those of many existing therapies. These 
agents have consistently been found to lower blood glucose and hemoglobin A1c (HbA1c) Drug, Healthcare and Patient Safety 2010:2 
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levels, and the safety and tolerability of these medications 
have generally been good.
Although the potential for clinical use of DPP-4 inhibitors 
is extensive, the use of this drug class has not been formally 
recommended by all expert panels. In early 2009, the American 
Diabetes Association (ADA) and European Association for the 
Study of Diabetes (EASD) released a consensus statement for 
management of type 2 diabetes, including an updated algo-
rithm for medication management. This algorithm focuses on 
lifestyle modifications and use of well-validated core therapies. 
Other than exenatide, which is listed as a “less-well-validated 
therapy,” incretin-based therapies are not included. Reasons 
given for the exclusion of the DPP-4 inhibitor class from 
the algorithm are that these agents are no more effective in 
lowering glucose than is insulin; that the DPP-4 inhibitors 
have unestablished long-term safety; and that they are more 
expensive than insulin.4 However, data continue to accrue for 
these agents, and there may be selected cases in which use of 
these medications would be preferable to more traditionally 
prescribed therapies. This review will summarize the existing 
information on incretin physiology, as well as the efficacy, 
safety, and tolerability of the DPP-4 inhibitors.
Physiology
incretin hormones and the incretin effect
Incretins are a group of insulinotropic hormones that are 
secreted by the gut in response to food intake. The class 
of hormones was first discovered in 1902, and in 1964 the 
incretin effect was described.5–7 The incretin effect refers to the 
more robust increase in insulin secretion in response to orally 
ingested glucose, as compared to the response elicited by 
glucose given intravenously. In the seminal trials, this effect 
was maintained despite the presence of higher blood glucose 
levels during the intravenous infusion.6,7 Subsequently, more 
details have emerged about the two hormones largely respon-
sible for the incretin effect: glucagon-like peptide (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP).
GLP-1 is the most potent known incretin. The level of 
GLP-1 rises quickly in response to food ingestion; this has 
direct effects on pancreatic endocrine function, including 
both insulin release from the beta cells and suppression of 
glucagon release from the alpha cells. There is some limited 
evidence that GLP-1 also acts at peripheral tissues to improve 
insulin utilization.8 Other effects of GLP-1 include slowed 
gastric emptying and the promotion of satiety at the level of 
the central nervous system.9 GIP, the other well-described 
but perhaps less well understood incretin hormone, promotes 
similar food and glucose-dependent insulin release. However, 
as opposed to GLP-1, it may exert a stimulatory effect on 
glucagon release.10 An important feature of both incretin 
hormones is that their activity is glucose-dependent: glucose-
lowering activity ceases when blood glucose levels fall below 
65 mg/dL.11 Furthermore, in animal models, both GLP-1 
and GIP are suspected to have a stimulatory effect upon the 
growth, proliferation, and differentiation of beta cells.9 The 
half-lives of GLP-1 and GIP are only a few minutes long, 
as they are rapidly degraded to largely inactive metabolites 
by DPP-4.11
incretin hormones and DPP-4 
in type 2 diabetes
In individuals with type 2 diabetes, the incretin effect appears 
to be blunted.12 This blunting has been attributed to 2 factors: 
GLP-1 levels are lower and GIP exerts a lesser physiologic effect 
than seen in normoglycemic individuals. Responsiveness to 
GLP-1 is generally preserved; infusion of GLP-1 to individuals 
with diabetes has been shown to lower both postprandial and 
fasting blood glucose levels.11,13 Conversely, there appear to be 
relatively normal levels of GIP in persons with type 2 diabetes, 
but their physiologic response to GIP is diminished.14 Whether 
or not abnormalities in DPP-4 levels or degradative activity 
exist in patients with diabetes is still unclear.
The administration of DPP-4 inhibitors to individuals with 
type 2 diabetes has been shown to raise levels of endogenous 
GLP-1 and GIP, which in turn results in a glucose-appropriate 
increase in insulin secretion and suppression of glucagon 
release.15 In patients with type 2 diabetes, administration 
of DPP-4 inhibitors has been shown to improve markers of 
insulin processing, including homeostasis model assessment 
of beta cell function (HOMA-β) and the proinsulin:insulin 
ratio.16 Furthermore, there are animal data to suggest that 
pancreatic beta cell mass may be preserved; beta cells may 
even be stimulated to grow and proliferate in the presence 
of these agents.17 However, no comparable anatomic data in 
humans are available.
Other roles of DPP-4 and homologous 
enzymes
DPP-4 circulates in soluble form in the plasma and is 
responsible for the inactivation of a number of hormones 
and peptides.18 In addition to the incretin hormones, these 
include substance P, whose fragment byproduct is important 
for sensory nerve transmission, and chemokines associated 
with interferon induction, macrophage signaling, eosinophil 
recruitment, and inhibition of mononuclear HIV-1 infec-
tion.19,20 DPP-4 inhibitors may also have a role in neuropeptide Drug, Healthcare and Patient Safety 2010:2 
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signaling by prolonging the action of neuropeptide Y and 
growth hormone-releasing hormone.21
In addition to the soluble form, there is a membrane-bound 
form of DPP-4, also called CD26, with an extracellular enzy-
matic domain and an intracellular domain involved with signal 
transduction cascades. Membrane-bound DPP-4 is found in 
epithelial cells, leukocytes, and other human tissues, including 
mammary glands, uterus, placenta, adrenal glands, exocrine 
pancreas, lymph nodes, gastrointestinal tract, and kidney.18,19 It 
has multiple roles, with apparent involvement in T-lymphocyte 
activation.20 DPP-4 levels have been found to be reduced 
in association with chronic rhinosinusitis and increased in 
association with multiple sclerosis and Graves’ disease.21 
Abnormal expression of both the soluble and membrane-bound 
forms has been associated with prostate cancer, melanoma, 
rheumatic diseases, HIV , and hepatitis C infection.19 In addi-
tion, T-cell hematologic malignancies, including lymphomas 
and lymphoproliferative disorders, have been associated with 
altered expression of DPP-4.19,20 Furthermore, rat transplanta-
tion studies indicate that DPP-4 inhibition may delay cardiac 
allograft rejection.19 It is as yet unclear to what extent this 
membrane-bound enzyme can be affected by pharmacological 
DPP-4 inhibition in vivo in humans.19,22,23
DPP-4 shares homology with other enzymes through a 
common enzymatic cleaving mechanism.18,22 These include 
DPP-7 (also called quiescent cell proline dipeptidase and 
DPP-2), DPP-8, DPP-9, fibroblast activation protein (FAP), 
attractin, and DPP-4β.22 Direct inhibition of DPP-7, DPP-8, 
and DPP-9 has been investigated in animal models. Admin-
istration of DPP-8 and DPP-9 inhibitors was associated with 
alopecia, thrombocytopenia, splenomegaly, reticulopenia, 
and gastrointestinal toxicity, while administration of DPP-7 
inhibitors was associated with reduced reticulocyte count.18,22 
Of the commercially available DPP-4 inhibitors sitagliptin, 
saxagliptin, and vildagliptin, interactions have been seen 
in vitro with only DPP-8 and DPP-9.24 However, no clear 
indication of DPP-8/DPP-9-related adverse events has been 
observed in clinical trials.24 It will be important for future 
development to focus on drugs that are specific inhibitors of 
DPP-4, and, if possible, of only the soluble form. Furthermore, 
investigations need to be conducted to examine effects of 
existing DPP-4 inhibitors in patients who are at risk for or who 
are affected by infectious and inflammatory conditions.
Pharmacokinetics of available 
agents
The mechanism of action of the various DPP-4 inhibitors 
appears to be similar. All of the named therapies inhibit 
DPP-4 activity by greater than 80%, which is the level of 
inhibition at which maximal glucose lowering is seen.25 
Vildagliptin is metabolized at the kidney prior to excre-
tion, saxagliptin is partially metabolized by the liver, and 
sitagliptin is largely unmetabolized prior to excretion by 
the kidney.26–29
Sitagliptin was the first commercially available DPP-4 
inhibitor, and the agent with which there is to date the most 
clinical experience. Sitagliptin is dosed at 100 mg daily; in 
healthy patients, this dose inhibits DPP-4 activity by 80% 
over 24 hours. Sitagliptin is approved for use in patients 
with renal insufficiency, although a dose reduction is neces-
sary in patients with moderate or severe renal dysfunction. 
Sitagliptin should be reduced to 50 mg daily for creatinine 
clearance 30 to 50 mL/min and to 25 mg daily for cre-
atinine clearance 30 mL/min.30,31 The medication may be 
taken once daily with or without food. Sitagliptin does not 
induce the CYP3A4 system and is not expected to interact 
with drugs metabolized through this pathway. Adverse 
drug–drug interactions have not been seen in studies evaluat-
ing combinations with glyburide, metformin, rosiglitazone, 
and pioglitazone.32–35 Outcomes data from trials of sitagliptin 
used in conjunction with insulin are not yet available. Drug 
metabolism does not differ between obese and lean sub-
jects.27 Sitagliptin has been studied in patients with diverse 
ethnic backgrounds, including Japanese, Korean, Chinese, 
and Indian subjects, with apparent similar activity in all of 
these groups.36,37
Vildagliptin is prescribed at dosages of 50 mg once or 
twice daily; absorption is not affected by food intake.38 It 
has not been studied in patients with renal dysfunction, but 
renal clearance of the drug was noted to be reduced in elderly 
subjects.39 Similar to sitagliptin, it is excreted predominantly 
in the urine, although only 22% remains unmetabolized at 
the time of excretion. Metabolism occurs at the level of the 
kidney and not through the CYP3A4 system, thus vildagliptin 
does not affect this enzymatic system.28 Coadministration of 
metformin and vildagliptin in patients with type 2 diabetes 
resulted in small and clinically insignificant effects on the 
pharmacokinetics of each drug; however, neither drug should 
require a dose adjustment in the presence of the other.40 
Significant drug interactions have not been seen in studies 
with glyburide, pioglitazone, ramipril, amlodipine, valsartan, 
simvastatin, digoxin, or warfarin.41–45 Drug metabolism does 
not appear to be affected by gender or body mass index 
(BMI).38 The pharmacokinetics of vildagliptin do not appear 
to differ significantly in the Chinese population compared to 
other ethnic groups studied.46Drug, Healthcare and Patient Safety 2010:2 10
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Saxagliptin is the most recently approved DPP-4 
inhibitor. It is currently available as a once daily oral medica-
tion, usually dosed at 5 mg daily.47 Saxagliptin is rapidly and 
extensively absorbed after oral dosing and can be taken with 
or without food. Saxagliptin has an active metabolite, M2, 
which is also cleared primarily by the kidneys. Saxagliptin is 
metabolized in part by the CYP3A4/5 enzymes, and its con-
comitant use with strong CYP3A4/5 inhibitors significantly 
increases the drug concentration. If such a drug combination 
is necessary, the saxagliptin dose should be decreased to 
2.5 mg daily. In patients with renal dysfunction evidenced 
by a creatinine clearance of 50 mL/min, dose reduction to 
2.5 mg daily is also recommended.29
Alogliptin and linagliptin are DPP-4 inhibitors in 
development but not yet commercially available. In brief, 
alogliptin is also a rapidly absorbed oral medication, with 
an activity half-life of 12 to 21 hours and predominantly 
renal excretion. At the doses likely to be recommended 
for clinical use, inhibition of DPP-4 is greater than 90%.48 
Linagliptin given at doses of 5 and 10 mg daily to men with 
type 2 diabetes resulted in DPP-4 inhibition of greater than 
90%. It appears to have a long terminal half-life compared 
to the other agents – around 130 hours – leading to sustained 
inhibition of DPP-4 activity. Excretion of linagliptin is pre-
dominantly renal.49
None of the DPP-4 inhibitors have been studied in preg-
nant or lactating women, thus their use in these populations 
cannot be recommended.
Efficacy
Glucose-lowering effects (Table 1)
DPP-4 inhibitors have been vigorously examined in random-
ized controlled trials and have generally been found to lower 
HbA1c levels significantly more than placebo. Sitagliptin and 
vildagliptin are the most studied, and two major meta-analyses 
have been performed on available trial data.50,51 Amori et al 
determined that the overall weighted mean placebo-subtracted 
HbA1c reduction for these two drugs is 0.74%.50 In their 2009 
meta-analysis, Monami et al examined both published and 
unpublished data of sitagliptin and vildagliptin efficacy. 
The average placebo-subtracted HbA1c reductions were 
0.70% and 0.68% respectively.51 Similar HbA1c reductions 
with these two drugs have been seen in trials of both mono-
therapy and add-on therapy. Sitagliptin has been examined 
in combination with metformin, glimepiride, metformin plus 
glimepiride, and pioglitazone.32,52–55 Noninferiority compari-
sons of glucose lowering have found that sitagliptin therapy 
is noninferior to glipizide or rosiglitazone but somewhat less 
effective than full-dose metformin or exenatide.54,56–58 Vilda-
gliptin has been examined in combination with metformin, 
glimepiride, pioglitazone, and insulin.59–63 Noninferiority 
comparisons have concluded that vildagliptin is similar in 
efficacy to rosiglitazone, pioglitazone, or acarbose, but is not 
as effective as metformin.64–69
Two studies of sitagliptin monotherapy and 1 study of 
vildagliptin monotherapy reported substantially larger reduc-
tions in HbA1c for patients with high baseline HbA1c values. 
Raz et al reported a trial of sitagliptin 100 mg daily, which 
resulted in a mean placebo-subtracted HbA1c reduction of 
1.2% for the group with baseline HbA1c 9% as compared 
to reductions of 0.44% for baseline HbA1c 8% and 0.6% 
for baseline 8% to 9%.16 Aschner et al reported similar mean 
placebo-subtracted reductions: 0.57%, 0.81%, and 1.52% for 
baseline HbA1c of  8%, 8% to 9%, and  9%, respectively.70 
Pratley et al reported a trial of vildagliptin 25 mg twice daily 
resulting in a mean placebo-subtracted HbA1c reduction of 
0.6% in patients with baseline HbA1c  8% and a reduction 
of 1.2% in those with baseline of 8% to 9.5%.71 Interestingly, 
upon meta-analysis, there was a nonsignificant trend toward 
a greater reduction of HbA1c in trials enrolling patients with 
a mean baseline HbA1c less than 8%.51 A clear explanation 
for this discrepancy is not currently available.
Five efficacy trials for saxagliptin have been published, 
with mean placebo-subtracted HbA1c reductions ranging from 
0.45% to 0.83%.47,72–74 However, Jadzinsky et al recently 
reported a large, 24-week randomized, controlled trial of 
saxagliptin 10 mg versus a combination of saxagliptin and 
metformin; a 1.7% mean placebo-subtracted HbA1c reduction 
was seen in the saxagliptin monotherapy group. This trial had 
a higher mean baseline HbA1c level, 9.5%, compared to other 
saxagliptin monotherapy trials, where mean baseline HbA1c 
levels otherwise ranged from 7.8% to 8.4%.47,72–75 Rosenstock 
et al reported a similarly large reduction from baseline of 
1.87% in a small open-label cohort with a mean baseline 
HbA1c of 10.7%.47 Efficacy of saxagliptin was maintained in 
two 24-week combination trials, one each with metformin 
and glyburide.74,75
Three efficacy trials have been reported for alogliptin, 
which have shown mean placebo-subtracted HbA1c reduc-
tions ranging from 0.39% to 0.58%. Monotherapy data are 
not available, but combinations of alogliptin with metfor-
min, glyburide, and insulin appear to yield similar glucose-
lowering effects.76–78
Efficacy data for linagliptin are pending; currently 
2 trials are recruiting participants. The first will examine Drug, Healthcare and Patient Safety 2010:2 11
DPP-4 inhibitors for type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
D
i
p
e
p
t
i
d
y
l
 
p
e
p
t
i
d
a
s
e
 
i
n
h
i
b
i
t
o
r
s
 
e
f
fi
c
a
c
y
 
t
r
i
a
l
s
 
s
u
m
m
a
r
y
S
t
u
d
y
 
a
u
t
h
o
r
N
u
m
b
e
r
 
p
a
t
i
e
n
t
s
D
o
s
e
C
o
m
p
a
r
e
d
 
t
o
A
d
d
-
o
n
 
t
o
T
r
i
a
l
 
d
u
r
a
t
i
o
n
B
a
s
e
l
i
n
e
 
m
e
a
n
 
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
M
e
a
n
 
h
e
m
o
g
l
o
b
i
n
 
 
A
1
c
 
r
e
d
u
c
t
i
o
n
a
S
i
t
a
g
l
i
p
t
i
n
r
a
z
1
6
5
2
1
1
0
0
 
o
r
 
2
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
8
 
w
e
e
k
s
8
.
1
%
1
0
0
 
m
g
:
 
0
.
6
%
2
0
0
 
m
g
:
 
0
.
4
8
%
A
s
c
h
n
e
r
7
0
7
4
1
1
0
0
 
o
r
 
2
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
0
%
1
0
0
 
m
g
:
 
0
.
7
9
%
2
0
0
 
m
g
:
 
0
.
9
4
%
S
c
o
t
t
8
2
7
4
3
5
,
 
1
2
.
5
,
 
2
5
,
 
5
0
 
m
g
 
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
2
 
w
e
e
k
s
7
.
9
%
r
a
n
g
e
:
 
0
.
3
8
%
–
0
.
7
7
%
 
 
(
d
o
s
e
-
d
e
p
e
n
d
e
n
t
 
r
e
s
p
o
n
s
e
)
5
0
 
m
g
 
b
i
d
:
 
0
.
7
7
%
H
a
n
e
fi
e
l
d
8
1
5
5
5
2
5
,
 
5
0
,
 
1
0
0
 
m
g
 
 
d
a
i
l
y
,
 
5
0
 
m
g
 
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
2
 
w
e
e
k
s
7
.
6
%
–
7
.
8
%
r
a
n
g
e
:
 
0
.
3
9
%
–
0
.
5
6
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
0
.
5
6
%
r
a
z
5
2
1
9
0
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
3
0
 
w
e
e
k
s
9
.
2
%
0
.
9
4
%
C
h
a
r
b
o
n
n
e
l
5
3
7
0
1
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
2
4
 
w
e
e
k
s
8
%
0
.
6
5
%
S
c
o
t
t
5
4
2
7
3
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
1
8
 
w
e
e
k
s
7
.
7
%
0
.
5
1
%
H
e
r
m
a
n
s
e
n
5
5
4
4
1
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
G
l
i
m
e
p
e
r
i
d
e
 
o
r
 
 
g
l
i
m
e
p
r
i
d
e
 
+
 
m
e
t
f
o
r
m
i
n
2
4
 
w
e
e
k
s
8
.
3
%
0
.
7
4
%
 
(
o
v
e
r
a
l
l
)
G
l
i
m
e
p
e
r
i
d
e
 
o
n
l
y
:
 
0
.
8
9
%
G
l
i
m
e
p
e
r
i
d
e
 
+
 
m
e
t
f
o
r
m
i
n
:
 
0
.
5
7
%
r
o
s
e
n
s
t
o
c
k
3
2
3
5
3
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
P
i
o
g
l
i
t
a
z
o
n
e
2
4
 
w
e
e
k
s
8
.
0
%
0
.
7
0
%
G
o
l
d
s
t
e
i
n
5
6
1
0
9
1
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
 
o
r
 
m
e
t
f
o
r
m
i
n
 
 
o
r
 
s
i
t
a
g
l
i
p
t
i
n
/
m
e
t
f
o
r
m
i
n
 
 
c
o
m
b
i
n
a
t
i
o
n
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
8
%
M
2
0
0
0
/
S
1
0
0
:
 
2
.
0
7
%
M
1
0
0
0
/
S
1
0
0
:
 
1
.
5
7
%
M
2
0
0
0
:
 
1
.
3
0
%
M
1
0
0
0
:
 
0
.
9
9
%
S
1
0
0
:
 
0
.
8
3
%
N
a
u
c
k
5
7
1
1
7
2
1
0
0
 
m
g
 
d
a
i
l
y
G
l
i
p
i
z
i
d
e
 
5
 
t
o
 
2
0
 
m
g
 
d
a
i
l
y
M
e
t
f
o
r
m
i
n
5
2
 
w
e
e
k
s
7
.
5
%
0
.
6
7
%
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
–
 
 
n
o
n
i
n
f
e
r
i
o
r
 
t
o
 
g
l
i
p
i
z
i
d
e
D
e
F
r
o
n
z
o
5
8
6
1
1
0
0
 
m
g
 
d
a
i
l
y
e
x
e
n
a
t
i
d
e
 
1
0
 
µ
g
 
 
t
w
i
c
e
 
d
a
i
l
y
M
e
t
f
o
r
m
i
n
2
 
w
e
e
k
s
,
 
w
i
t
h
 
 
2
-
w
e
e
k
 
c
r
o
s
s
-
o
v
e
r
8
.
5
%
P
o
s
t
-
p
r
a
n
d
i
a
l
 
g
l
u
c
o
s
e
 
 
m
e
a
s
u
r
e
d
 
a
s
 
o
u
t
c
o
m
e
:
e
x
e
n
:
 
1
3
3
 
m
g
/
d
L
S
i
t
a
:
 
2
0
8
 
m
g
/
d
L
(
d
i
f
f
e
r
e
n
c
e
 
f
o
l
l
o
w
e
d
 
 
d
r
u
g
 
a
f
t
e
r
 
c
r
o
s
s
-
o
v
e
r
)
S
c
o
t
t
5
4
2
7
3
1
0
0
 
m
g
 
d
a
i
l
y
r
o
s
i
g
l
i
t
a
z
o
n
e
 
8
 
m
g
M
e
t
f
o
r
m
i
n
1
8
 
w
e
e
k
s
7
.
7
%
0
.
5
1
%
 
–
 
n
o
n
i
n
f
e
r
i
o
r
 
 
t
o
 
r
o
s
i
g
l
i
t
a
z
o
n
e
V
i
l
d
a
g
l
i
p
t
i
n
P
r
a
t
l
e
y
7
1
9
8
2
5
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
2
 
w
e
e
k
s
8
.
0
%
0
.
6
%
(
C
o
n
t
i
n
u
e
d
)Drug, Healthcare and Patient Safety 2010:2 12
Cox et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
 
a
u
t
h
o
r
N
u
m
b
e
r
 
p
a
t
i
e
n
t
s
D
o
s
e
C
o
m
p
a
r
e
d
 
t
o
A
d
d
-
o
n
 
t
o
T
r
i
a
l
 
d
u
r
a
t
i
o
n
B
a
s
e
l
i
n
e
 
m
e
a
n
 
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
M
e
a
n
 
h
e
m
o
g
l
o
b
i
n
 
 
A
1
c
 
r
e
d
u
c
t
i
o
n
a
P
i
-
S
u
n
y
e
r
1
0
7
3
5
4
5
0
 
m
g
 
d
a
i
l
y
,
 
 
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
,
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
4
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
5
%
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
:
 
0
.
7
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
0
.
9
%
D
e
j
a
g
e
r
1
0
8
6
3
2
5
0
 
m
g
 
d
a
i
l
y
,
 
 
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
,
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
5
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
8
%
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
:
 
0
.
7
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
0
.
9
%
S
c
h
e
r
b
a
u
m
1
0
9
3
0
6
5
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
5
2
 
w
e
e
k
s
6
.
7
%
0
.
3
%
S
c
h
e
r
b
a
u
m
8
3
1
3
1
5
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
0
4
 
w
e
e
k
s
 
(
5
2
 
w
e
e
k
s
 
 
t
h
e
n
 
4
-
w
e
e
k
 
w
a
s
h
-
o
u
t
,
 
 
t
h
e
n
 
5
2
 
w
e
e
k
s
)
6
.
6
%
1
 
y
e
a
r
:
 
0
.
3
%
2
 
y
e
a
r
s
:
 
0
.
5
%
r
i
s
t
i
c
8
4
2
7
9
2
5
,
 
5
0
,
 
1
0
0
 
m
g
 
d
a
i
l
y
,
 
 
2
5
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
2
 
w
e
e
k
s
7
.
7
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
5
6
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
0
.
5
3
%
O
t
h
e
r
 
g
r
o
u
p
s
 
w
e
r
e
 
n
o
t
 
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
 
d
i
f
f
e
r
e
n
t
 
f
r
o
m
 
p
l
a
c
e
b
o
S
c
h
w
e
i
z
e
r
6
8
7
8
0
1
0
0
 
m
g
 
d
a
i
l
y
M
e
t
f
o
r
m
i
n
D
i
e
t
/
e
x
e
r
c
i
s
e
5
2
 
w
e
e
k
s
8
.
7
%
v
i
l
d
a
g
l
i
p
t
i
n
:
 
1
.
0
%
M
e
t
f
o
r
m
i
n
:
 
1
.
4
%
v
i
l
d
a
g
l
i
p
t
i
n
 
e
f
f
e
c
t
 
d
i
d
 
 
n
o
t
 
r
e
a
c
h
 
s
t
a
t
i
s
t
i
c
a
l
 
 
n
o
n
i
n
f
e
r
i
o
r
i
t
y
G
o
k
e
6
9
4
6
3
1
0
0
 
m
g
 
d
a
i
l
y
M
e
t
f
o
r
m
i
n
D
i
e
t
/
e
x
e
r
c
i
s
e
1
0
4
 
w
e
e
k
s
 
(
5
2
 
w
e
e
k
 
e
x
t
e
n
s
i
o
n
 
o
f
 
p
r
e
v
i
o
u
s
 
 
s
t
u
d
y
6
8
)
v
i
l
d
a
g
l
i
p
t
i
n
:
 
8
.
4
%
 
M
e
t
f
o
r
m
i
n
:
 
8
.
8
%
v
i
l
d
a
g
l
i
p
t
i
n
:
 
1
.
0
%
M
e
t
f
o
r
m
i
n
:
 
1
.
5
%
v
i
l
d
a
g
l
i
p
t
i
n
 
e
f
f
e
c
t
 
d
i
d
 
n
o
t
 
 
r
e
a
c
h
 
s
t
a
t
i
s
t
i
c
a
l
 
n
o
n
i
n
f
e
r
i
o
r
i
t
y
r
o
s
e
n
s
t
o
c
k
6
4
7
8
6
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
r
o
s
i
g
l
i
t
a
z
o
n
e
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
7
%
1
.
1
%
 
–
 
n
o
n
i
n
f
e
r
i
o
r
 
 
t
o
 
r
o
s
i
g
l
i
t
a
z
o
n
e
r
o
s
e
n
s
t
o
c
k
6
5
6
0
7
1
0
0
 
m
g
 
d
a
i
l
y
P
i
o
g
l
i
t
a
z
o
n
e
 
3
0
 
m
g
 
v
s
 
 
v
i
l
d
a
g
l
i
p
t
i
n
 
+
 
p
i
o
g
l
i
t
a
z
o
n
e
 
c
o
m
b
i
n
a
t
i
o
n
 
(
1
0
0
/
3
0
 
m
g
 
d
a
i
l
y
 
o
r
 
5
0
/
1
5
 
m
g
 
d
a
i
l
y
)
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
7
%
v
i
l
d
a
g
l
i
p
t
i
n
:
 
1
.
1
%
P
i
o
g
l
i
t
a
z
o
n
e
:
 
1
.
4
%
1
0
0
/
3
0
 
m
g
 
d
a
i
l
y
:
 
1
.
9
%
5
0
/
1
5
 
m
g
 
d
a
i
l
y
:
 
1
.
7
%
P
a
n
6
7
6
6
1
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
A
c
a
r
b
o
s
e
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
8
.
6
%
v
i
l
d
a
g
l
i
p
t
i
n
:
 
1
.
4
%
A
c
a
r
b
o
s
e
:
 
1
.
3
%
B
o
s
i
5
9
4
8
4
5
0
 
o
r
 
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
2
4
 
w
e
e
k
s
8
.
4
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
7
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
1
.
1
%
A
h
r
e
n
6
0
5
7
5
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
5
2
 
w
e
e
k
s
7
.
7
%
1
.
0
%
G
a
r
b
e
r
6
1
5
1
5
5
0
 
m
g
 
d
a
i
l
y
 
 
o
r
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
G
l
i
m
e
p
e
r
i
d
e
 
 
4
 
m
g
 
d
a
i
l
y
2
4
 
w
e
e
k
s
8
.
5
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
6
%
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
:
 
0
.
7
%Drug, Healthcare and Patient Safety 2010:2 13
DPP-4 inhibitors for type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
G
a
r
b
e
r
6
2
4
6
3
5
0
 
o
r
 
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
P
i
o
g
l
i
t
a
z
o
n
e
2
4
 
w
e
e
k
s
8
.
7
%
5
0
 
m
g
 
d
a
i
l
y
:
 
0
.
8
%
1
0
0
 
m
g
 
d
a
i
l
y
:
 
1
.
0
%
F
o
n
s
e
c
a
6
3
2
9
6
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
P
l
a
c
e
b
o
i
n
s
u
l
i
n
2
4
 
w
e
e
k
s
8
.
4
%
0
.
3
%
B
o
l
l
i
6
6
5
7
6
5
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
P
i
o
g
l
i
t
a
z
o
n
e
M
e
t
f
o
r
m
i
n
2
4
 
w
e
e
k
s
8
.
4
%
0
.
9
%
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
–
 
 
n
o
n
i
n
f
e
r
i
o
r
 
t
o
 
p
i
o
g
l
i
t
a
z
o
n
e
S
a
x
a
g
l
i
p
t
i
n
r
o
s
e
n
s
t
o
c
k
7
2
3
3
8
2
.
5
,
 
5
,
 
1
0
,
 
2
0
 
 
o
r
 
4
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
1
2
 
w
e
e
k
s
7
.
9
%
0
.
4
5
%
–
0
.
6
3
%
r
o
s
e
n
s
t
o
c
k
7
2
8
5
1
0
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
6
 
w
e
e
k
s
7
.
8
%
0
.
7
3
%
r
o
s
e
n
s
t
o
c
k
4
7
4
0
1
2
.
5
,
 
5
,
 
o
r
 
1
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
M
a
i
n
 
t
r
e
a
t
m
e
n
t
 
 
c
o
h
o
r
t
:
 
7
.
9
%
O
p
e
n
-
l
a
b
e
l
 
 
c
o
h
o
r
t
:
 
1
0
.
7
%
M
a
i
n
 
t
r
e
a
t
m
e
n
t
 
c
o
h
o
r
t
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
6
2
%
5
 
m
g
 
d
a
i
l
y
:
 
0
.
6
5
%
1
0
 
m
g
 
d
a
i
l
y
:
 
0
.
7
3
%
O
p
e
n
 
l
a
b
e
l
 
c
o
h
o
r
t
:
1
.
8
7
%
D
e
F
r
o
n
z
o
7
3
7
4
3
2
.
5
,
 
5
,
 
o
r
 
1
0
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
2
4
 
w
e
e
k
s
8
.
0
%
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
7
3
%
5
 
m
g
 
d
a
i
l
y
:
 
0
.
8
3
%
1
0
 
m
g
 
d
a
i
l
y
:
 
0
.
7
2
%
J
a
d
z
i
n
s
k
y
7
5
1
3
0
6
1
0
 
m
g
 
d
a
i
l
y
M
e
t
f
o
r
m
i
n
 
o
r
 
 
m
e
t
f
o
r
m
i
n
 
+
 
 
s
a
x
a
g
l
i
p
t
i
n
 
5
 
m
g
 
 
o
r
 
1
0
 
m
g
 
d
a
i
l
y
D
i
e
t
/
e
x
e
r
c
i
s
e
2
4
 
w
e
e
k
s
9
.
4
%
–
9
.
6
%
S
a
x
a
b
l
i
p
t
i
n
:
 
1
.
7
%
M
e
t
f
o
r
m
i
n
:
 
2
.
0
%
C
o
m
b
i
n
a
t
i
o
n
 
(
b
o
t
h
)
:
 
2
.
5
%
(
C
o
m
b
i
n
a
t
i
o
n
s
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
 
s
u
p
e
r
i
o
r
 
t
o
 
e
i
t
h
e
r
 
 
m
o
n
o
t
h
e
r
a
p
y
)
C
h
a
c
r
a
7
4
7
6
8
2
.
5
 
o
r
 
5
 
m
g
 
d
a
i
l
y
G
l
y
b
u
r
i
d
e
 
u
p
t
i
t
r
a
t
e
d
 
 
t
o
 
1
5
 
m
g
 
d
a
i
l
y
G
l
y
b
u
r
i
d
e
 
1
0
 
m
g
 
 
m
a
x
i
m
u
m
2
4
 
w
e
e
k
s
8
.
4
%
–
8
.
5
%
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
5
4
%
5
 
m
g
 
d
a
i
l
y
:
 
0
.
6
4
%
G
l
y
b
u
r
i
d
e
 
u
p
t
i
t
r
a
t
i
o
n
:
 
+
0
.
0
8
%
A
l
o
g
l
i
p
t
i
n
N
a
u
c
k
7
6
5
2
7
1
2
.
5
 
o
r
 
2
5
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
2
6
 
w
e
e
k
s
7
.
9
%
–
8
.
0
%
1
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
5
%
2
5
 
m
g
 
d
a
i
l
y
;
 
0
.
5
%
P
r
a
t
l
e
y
7
7
5
0
0
1
2
.
5
 
o
r
 
2
5
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
G
l
y
b
u
r
i
d
e
2
6
 
w
e
e
k
s
8
.
1
%
1
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
3
9
%
2
5
 
m
g
 
d
a
i
l
y
:
 
0
.
5
3
%
r
o
s
e
n
s
t
o
c
k
7
8
3
9
0
1
2
.
5
 
o
r
 
2
5
 
m
g
 
d
a
i
l
y
P
l
a
c
e
b
o
i
n
s
u
l
i
n
 
w
i
t
h
 
o
r
 
 
w
i
t
h
o
u
t
 
m
e
t
f
o
r
m
i
n
2
6
 
w
e
e
k
s
9
.
3
%
1
2
.
5
 
m
g
 
d
a
i
l
y
:
 
0
.
5
0
%
2
5
 
m
g
 
d
a
i
l
y
:
 
0
.
5
8
%
a
P
l
a
c
e
b
o
-
s
u
b
t
r
a
c
t
e
d
,
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
 
v
a
l
u
e
 
u
n
l
e
s
s
 
s
t
a
t
e
d
 
o
t
h
e
r
w
i
s
e
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
M
2
0
0
0
/
S
1
0
0
,
 
m
e
t
f
o
r
m
i
n
 
2
0
0
0
 
m
g
,
 
s
i
t
a
g
l
i
p
t
i
n
 
1
0
0
 
m
g
;
 
M
1
0
0
0
/
S
1
0
0
,
 
m
e
t
f
o
r
m
i
n
 
1
0
0
0
 
m
g
,
 
s
i
t
a
g
l
i
p
t
i
n
 
1
0
0
 
m
g
;
 
M
2
0
0
0
,
 
m
e
t
f
o
r
m
i
n
 
2
0
0
0
 
m
g
;
 
M
1
0
0
0
,
 
m
e
t
f
o
r
m
i
n
 
1
0
0
0
 
m
g
;
 
S
1
0
0
,
 
s
i
t
a
g
l
i
p
t
i
n
 
1
0
0
 
m
g
.Drug, Healthcare and Patient Safety 2010:2 14
Cox et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
glucose-lowering effects of linagliptin 2.5 mg twice daily 
as add on to metformin,79 and the second will examine its 
efficacy as add-on therapy to insulin.80
effects of therapies on beta cell function, 
alpha cell function, and peripheral glucose 
metabolism
One attractive feature of DPP-4 inhibitors is the potential 
beneficial effect they exert on pancreatic beta cells. In efficacy 
trials of sitagliptin, vildagliptin, and saxagliptin, investigators 
have consistently reported improvements in markers of beta 
cell function, including HOMA-β, insulin:proinsulin ratio, 
glucose to insulin concentration-time curve (AUC) ratio, 
and the insulinogenic index.32,52,53,55,59,61,62,70–72,81–85 Islet func-
tion has also been shown to improve with administration of 
vildagliptin in patients with impaired glucose tolerance that 
have not yet progressed to type 2 diabetes.86 However, it has 
not yet been shown that this therapy delays progression of the 
disease in these patients. Fasting insulin levels also increase 
with DPP-4 inhibition, further supporting an improvement 
in beta cell function. A small study conducted by D’Alessio 
et al examined fasting insulin production in patients with 
well-controlled type 2 diabetes on metformin or dietary 
therapy, given add-on treatment with vildagliptin. The study 
described DPP-4 induced improvement in fasting islet cell 
function even in patients with well-controlled diabetes.87 In 
rodent models, studies of DPP-4 inhibitors have demonstrated 
that exposure to these agents inhibits apoptosis, augments 
beta cell replication and increases beta cell mass.88 However, 
rodents have high rates of beta cell turnover, which may allow 
for a very robust physiologic response to DPP-4 inhibition; 
it is unclear whether the findings of beta cell proliferation 
and growth can be translated to humans.
Unlike the other DPP-4 inhibitors, alogliptin studies have 
not as clearly supported an improvement in beta cell function 
other than that demonstrated by glucose lowering. Although 
db/db mice treated with alogliptin showed improvement in 
markers of beta cell function, studies in humans have not 
documented improvement in HOMA-β or proinsulin:insulin 
ratio.89,76,77
In addition to their effects on the beta cells, DPP-4 
inhibitors appear to have effects on the alpha cells as well. 
Alpha cells are dysfunctional in patients with type 2 diabetes, 
resulting in unregulated glucagon production.90 As a result, 
hepatic glucose production is not suppressed during times of 
hyperglycemia. Incretin hormones enhance the sensitivity of 
alpha cells to glucose. Increases in incretin hormone levels 
via DPP-4 inhibition with both vildagliptin and sitagliptin 
have been shown to have this physiologic effect, demon-
strated by appropriately decreased post-prandial glucagon 
levels.8,91
There is evidence to suggest that vildagliptin may also 
improve peripheral glucose utilization, as assessed by Azuma 
et al with an insulin infusion study. The authors speculate 
that there may be a direct effect of GLP-1 or GIP on glucose 
uptake.8 Conversely, Hanefield et al examined measures of 
insulin resistance, specifically the quantitative insulin sensi-
tivity check index (QUICKI) and HOMA-insulin resistance, 
in a study of sitagliptin; there was no difference from placebo 
in these measures.81 Further data are needed to establish 
whether there is, in fact, an incretin effect at peripheral tissues 
or whether this may be a unique effect of vildagliptin.
Nonglycemic effects, including 
cardiovascular effects
In addition to the effects on glucose metabolism, incre-
tin hormones may also affect lipids, blood pressure, and 
cardiovascular health. Endogenous GLP-1 has been shown 
to slow gastric emptying, increase satiety, and reduce food 
intake.9 Despite the increase in endogenous GLP-1 levels with 
administration of DPP-4 inhibitors, these medications have 
not been shown to exert similar effects.92 When compared 
directly with exenatide, a GLP-1 agonist, patients taking 
exenatide had reduced caloric intake and slowed gastric 
emptying in response to that drug, while patients taking 
sitagliptin did not.58 GLP-1 agonist therapy has also been 
associated with mild systolic blood pressure reduction of 
2 to 6 mmHg; this effect has not yet been demonstrated with 
DPP-4 inhibitors.93 Finally, therapy with GLP-1 agonists is 
associated with weight loss, while the DPP-4 inhibitors are 
generally weight neutral.94,58
Vildagliptin and sitagliptin have been examined for lipid-
lowering effects, particularly for changes in post-prandial 
triglyceride levels. In an efficacy study comparing vilda-
gliptin with rosiglitazone, patients treated with vildagliptin 
50 mg twice daily experienced reductions in triglycerides 
(9%), total cholesterol (14%), low-density lipoprotein (LDL) 
cholesterol (16%), and non-high-density lipoprotein (HDL) 
cholesterol (16%); all were statistically greater reductions 
than those seen with rosiglitazone. Vildagliptin therapy also 
increased HDL cholesterol, although it was not to the same 
extent as rosiglitazone, 4% versus 9% respectively.64 Vilda-
gliptin therapy has been examined specifically for reduction 
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with type 2 diabetes; reductions in both apolipoprotein 
B48 and cholesterol components were reported.95 Modest 
improvements in HDL cholesterol, about 4%, and reductions 
in triglyceride levels of 9% have also been reported with 
sitagliptin therapy. Total, LDL, and non-HDL cholesterol 
were not improved.82 Reductions in lipid levels appear to 
be independent from the glucose-lowering effects of these 
drugs, as sulfonylureas and thiazolidinediones with similar 
glucose-lowering efficacy, have not shown the same lipid 
effects in head-to-head comparisons.64,82
Safety and tolerability
Side effects
There have been numerous individual trials and 3 large 
meta-analyses to examine the safety and tolerability of the 
DPP-4 inhibitors as a class.21,50,51 The analyses have shown 
that these medications are generally well-tolerated in the 
short term. With respect to hypoglycemia, the DPP-4 inhibi-
tors have performed well. Their use has not been commonly 
associated with any degree of hypoglycemia. Although a few 
individual trials have found an increase in mild hypoglycemia 
when DPP-4 inhibitors are combined with other antidiabetic 
medications,38,55,60,65 2 meta-analyses have shown that there 
has been no significant difference from placebo, even when 
DPP-4 inhibitors are combined with sulfonylureas or insu-
lin.21,51 Monami et al examined unpublished data and described 
five cases of severe hypoglycemia in sitagliptin monotherapy; 
these cases were fewer than those in sulfonylurea comparator 
groups and were not discussed in the published literature.51 
Another feature in favor of the use of DPP-4 medications is 
that they have not been associated with weight gain. Meta-
analyses of sitagliptin, vildagliptin, alogliptin, and saxagliptin 
concluded that there has been no clinically significant effect 
on BMI in placebo-controlled trials.51
Reported side effects have generally been mild, such as 
increased rate of headaches with vildagliptin and increased 
rates of upper respiratory tract infections with sitagliptin.51 
Increased rates of other mild infections, such as urinary 
tract infection, have been reported in individual trials and 
were associated with use of sitagliptin in a 2009 Cochrane 
review.21 However, a more recent meta-analysis did not 
confirm this association.51 In the postmarketing period, the 
use of sitagliptin has been associated with cases of mild to 
severe hypersensitivity reactions, including anaphylaxis, 
angioedema, and exfoliative skin conditions. These have 
occurred in the first few months of therapy; in one case, 
after the first dose. Continued use of or re-exposure to 
sitagliptin is contraindicated in patients who have experi-
enced hypersensitivity reactions.96 Vildagliptin has been 
associated with rare cases of hepatic dysfunction, and should 
not be used in patients with pre-existing moderate to severe 
hepatic failure.97 Vildagliptin was also associated with a 
skin blistering condition in nonclinical toxicology studies 
with primates. This has not been reported in human studies 
at recommended therapeutic dosages, and is not reported in 
post-marketing data.98 More studies are needed to examine 
the potential immunomodulatory effects of vildagliptin and 
determine whether they are greater than that seen with use 
of other agents in this class.
The US Food and Drug Administration (FDA) recently 
called attention to a number of cases of acute pancreatitis, 
which were temporally associated with the initiation of 
sitagliptin.99 This announcement raises concern given that a 
similar association had been observed with the GLP-1 ago-
nist exenatide.100 The classes of drugs that utilize the incretin 
pathway are known to have direct effects on the structure of 
the pancreas in rodent models, suggesting the possibility for a 
causal relationship with pancreatitis, although the mechanism 
is unclear. In one rodent study, use of GLP-1 receptor agonists 
was associated with increase in pancreatitis-associated gene 
expression but not with pancreatitis.101 Matveyenko et al 
conducted a rodent model study to examine the effects on the 
pancreas of metformin and sitagliptin in combination. The two 
drugs appeared to have synergistic effect to preserve beta-cell 
mass and function, but use of sitagliptin was associated with 
increased pancreatic ductal turnover, ductal metaplasia, and, 
in one rat, pancreatitis.102 These findings do raise concern; 
however, this information has yet to be confirmed in humans. 
Human data exist in the form of a retrospective analysis of 
around 88,000 patient hospitalization records, which exam-
ined rates of admission for acute pancreatitis in patients using 
incretin-based therapies (exenatide and sitagliptin) compared 
to matched groups of patients using metformin and glyburide. 
They found that hospitalizations for acute pancreatitis within 
1 year of initiation of the respective drugs were similar for the 
four medications, with a rate of 0.13% per year of patients on 
exenatide and 0.12% per year for patients on sitagliptin.103 Given 
that the human data at this point are limited to postmarketing 
reports and retrospective data analysis, the true relationship of 
pancreatitis to incretin-based therapy remains unknown. Given 
the baseline rate of pancreatitis in people with diabetes, it is 
currently difficult to know if reports of pancreatitis in people 
on incretin therapies are truly attributable to drug usage. Data 
accumulated from large, long-term trials with sitagliptin and 
other DPP-4 inhibitors may provide much needed information Drug, Healthcare and Patient Safety 2010:2 16
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regarding this relationship. For now, the FDA recommends 
that physicians warn patients about the potential risk as well 
as the symptoms of pancreatitis, and discontinue the drugs if 
symptoms or signs of pancreatitis develop.99
The FDA now requires that therapies approved to treat type 
2 diabetes should provide data to demonstrate that the therapy 
will not result in an unacceptable increase in cardiovascular 
risk.104 Saxagliptin was the first drug approved following 
establishment of this guideline; its use was not associated 
with an increased risk of cardiovascular events in pooled 
data from eight pre-marketing clinical trials.105 However, 
the number of cardiovascular events occurring during these 
trials was inadequate to confidently exclude a differential 
effect; thus a long-term cardiovascular outcomes trial of this 
medication will be required. Although analysis of data from 
early studies of sitagliptin and vildagliptin found that mor-
tality and cardiovascular event rates were similar between 
these drugs and comparators, no individual trial with these 
agents was powered to examine this outcome.51 A long-term 
cardiovascular outcomes trial of sitagliptin therapy in indi-
viduals at high risk for such complications began enrollment 
in December of 2008. The Trial Evaluating Cardiovascular 
Outcomes with Sitagliptin (TECOS) is an international trial 
of 14,000 individuals with diabetes and cardiovascular disease 
which will assess the impact of sitagliptin therapy on events 
including cardiovascular death, myocardial infarction, stroke, 
and hospitalization for unstable angina.106
Conclusion
Therapy for type 2 diabetes is complex; many patients 
require multiple medications to reach optimal glycemic tar-
gets. As outlined in the ADA/EASD algorithm for diabetes 
medications, there are multiple potential combinations of 
medications for any individual; the provider must consider 
co-morbidities and patient preferences when making these 
decisions. Although the DPP-4 inhibitor class is not yet well-
studied enough to have been included in the algorithm, studies 
suggest that these drugs’ mechanisms of action complement 
those of traditionally used diabetes medications. The DPP-4 
inhibitors have been criticized for having lower glucose-
lowering efficacy than other available therapies, particularly 
insulin.4 However, the active comparator trials data suggest 
that they can be as effective as more traditionally prescribed 
therapies. Furthermore, they are generally well tolerated, do 
not cause weight gain, and may provide some beta cell protec-
tion. Unlike many traditional medications, these drugs rarely 
cause hypoglycemia and some agents have no major contra-
indications to use. These attributes make this class of drugs 
attractive for use in the elderly, for those who have multiple 
co-morbidities precluding the use of other medications, and 
for those in whom insulin therapy proves difficult.
Data on these drugs continue to be accrued, and it is likely 
that the safety concerns related to the immune system and 
pancreatitis will be prospectively and more comprehensively 
addressed. Long-term trials are also needed to determine 
if preliminary data suggesting beta cell preservation will 
be borne out in clinical practice. Further investigations are 
also needed to examine long-term effects of these agents on 
cardiovascular outcomes and mortality.
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